BCL-2 is dispensable for thrombopoiesis and platelet survival

Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-X(L) and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Debrincat, M A, Pleines, I, Lebois, M, Lane, R M, Holmes, M L, Corbin, J, Vandenberg, C J, Alexander, W S, Ng, A P, Strasser, A, Bouillet, P, Sola-Visner, M, Kile, B T, Josefsson, E C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650559/
https://www.ncbi.nlm.nih.gov/pubmed/25880088
http://dx.doi.org/10.1038/cddis.2015.97

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650559/
https://www.ncbi.nlm.nih.gov/pubmed/25880088
http://dx.doi.org/10.1038/cddis.2015.97

Ejemplares similares